anti-BTN3A agonistic monoclonal antibody ICT01

A humanized agonistic monoclonal antibody directed against butyrophilin subfamily 3 member A (BTN3A; CD277), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-BTN3A agonistic monoclonal antibody ICT01 targets and binds to BTN3A present on epithelial and tumor cells. BTN3A binding may sensitize tumor cells to gamma 9 delta 2 (Vg9Vd2) T-cell killing. The Vg9Vd2 T cells secrete effector cytokines and exert a cytolytic effect on tumor cells. This may abrogate BTN3A-mediated tumor immunity and may enhance anti-tumor immune response. BTN3A, a member of the butyrophilin superfamily of immunomodulators, is upregulated in tumor cells.